ASND (Ascendis Pharma AS) Revenue: $1,008 Mil (TTM As of Mar. 2026)

What is Ascendis Pharma AS Revenue?

Ascendis Pharma AS ASND +2.52% 37 Revenue is $1,008 Mil as of Mar. 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

Ascendis Pharma AS's revenue for the three months ended in Mar. 2026 was $285 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $1,008 Mil. Ascendis Pharma AS's Revenue per Share for the three months ended in Mar. 2026 was $4.42. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $16.13.

During the past 12 months, the average Revenue per Share Growth Rate of Ascendis Pharma AS was 143.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 143.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 171.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was 54.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Ascendis Pharma AS's highest 3-Year average Revenue per Share Growth Rate was 245.10% per year. The lowest was -62.40% per year. And the median was 20.50% per year.

Ascendis Pharma AS (NAS:ASND) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Ascendis Pharma AS Revenue Related Terms

Ascendis Pharma AS Revenue Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Revenue Chart

Ascendis Pharma AS Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Revenue

Get a 7-Day Free Trial

8.79

54.21

290.86

380.78

843.25

Ascendis Pharma AS Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Revenue	Get a 7-Day Free Trial															109.14	182.29	250.74	289.81	285.09

ASND vs JAZZ, BBIO, EXEL: Revenue Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascendis Pharma AS Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Revenue distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Revenue falls into.

Save Embed

37GF Score

Ascendis Pharma AS ASND

Revenue is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Ascendis Pharma AS Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,008 Mil.

Frequently Asked Questions Learn more about Revenue →

What does a Revenue of $1,008 Mil mean?

Ascendis Pharma AS (ASND) has a Revenue of $1,008 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Ascendis Pharma AS and its competitors.

Is Ascendis Pharma AS's Revenue too high?

Ascendis Pharma AS's current Revenue is $1,008 Mil. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.

How does Ascendis Pharma AS's Revenue compare to JAZZ and BBIO?

Ascendis Pharma AS's Revenue of $1,008 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Revenue for a Biotechnology company?

A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Revenue mean?

A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Revenue is $1,008 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ascendis Pharma AS stock overvalued right now?

Ascendis Pharma AS (ASND) has a current Revenue of $1,008 Mil. The current Revenue is $1,008 Mil. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Revenue calculated?

Revenue is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Revenue is $1,008 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Industry Healthcare Biotechnology

Comparable Companies JAZZ BBIO EXEL IONS AXSM MDGL INSM INCY BMRN CYTK VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges A1SN34:Brazil

Address Tuborg Boulevard 12, Hellerup, DNK, 2900

Website https://www.ascendispharma.com

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

37GF Score

Get the complete analysis for ASND

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$274.50

Price

View ASND Analysis

See Revenue data for all stocks →